Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Constanze Kaiser"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Atezolizumab is a treatment for locally advanced/metastatic urothelial carcinoma (mUC). However, its use in patients with renal insufficiency or UC with mixed variant histology (MVH) is not well characterized.Objective To report efficacy a
Externí odkaz:
https://doaj.org/article/1d5e114dc6884499ae57a5fe02ce5812
Autor:
Andrea Necchi, Daniel Hennessy, Juliane Manitz, Toni K. Choueiri, Noah M. Hahn, Shaad Essa Abdullah, Chen Gao, Constanze Kaiser, Ashok K. Gupta, Sandy Srinivas, Andrea B. Apolo, Jonathan E. Rosenberg, Darren Tayama, Doris Makari, Gregory R. Pond, Guru Sonpavde, Dean F. Bajorin, Matthew D. Galsky, Thomas Powles, Petros Grivas, Robert Dreicer, Guenter Niegisch
Publikováno v:
J Urol
PURPOSE: A prognostic model for overall survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-1/PD-L1 inhibitors is necessary as existing models were constructed in the chemotherapy setting. MATERIALS AND METHODS: Patie
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAtezolizumab is a treatment for locally advanced/metastatic urothelial carcinoma (mUC). However, its use in patients with renal insufficiency or UC with mixed variant histology (MVH) is not well characterized.ObjectiveTo report efficacy and
Autor:
Hanzhe Zheng, Joaquim Bellmunt, Jean H. Hoffman-Censits, Darren Tayama, Sumanta K. Pal, Constanze Kaiser
Publikováno v:
European Urology. 73:800-806
Atezolizumab (anti-programmed death-ligand 1) was approved in the USA, Europe, and elsewhere for treatment-naive and platinum-treated locally advanced/metastatic urothelial carcinoma (mUC).To report efficacy and safety from an atezolizumab expanded a
Autor:
Jean H. Hoffman-Censits, Q. Zhu, Jose Luis Perez-Gracia, Constanze Kaiser, Christina Louise Derleth, Richard W. Joseph, Andrea Necchi, Darren Tayama, Daniel P. Petrylak, Beiying Ding, Jonathan E. Rosenberg, Yohann Loriot
Publikováno v:
Annals of Oncology. 28:3044-3050
Background Conventional criteria for tumor progression may not fully reflect the clinical benefit of immunotherapy or appropriately guide treatment decisions. The phase II IMvigor210 study demonstrated the efficacy and safety of atezolizumab, a progr
Autor:
Yohann Loriot, Nicholas J. Vogelzang, Constanze Kaiser, Rafael Morales-Barrera, Thomas Powles, Joseph Kim, Daniel P. Petrylak, Howard A. Burris, Marcella Fassò, Beiying Ding, Carol O'Hear, Joaquim Bellmunt, Fadi Braiteh
Importance Atezolizumab (anti–programmed death ligand 1) has demonstrated safety and activity in advanced and metastatic urothelial carcinoma, but its long-term clinical profile remains unknown. Objective To report long-term clinical outcomes with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a756bcf1edaf975efc711ccf1968e29
https://europepmc.org/articles/PMC5885219/
https://europepmc.org/articles/PMC5885219/
Autor:
Daniel P. Petrylak, Xiaodong Shen, Yohann Loriot, Jean H. Hoffman-Censits, Arjun Vasant Balar, Jonathan E. Rosenberg, Constanze Kaiser, Jose Luis Perez-Gracia, Q. Zhu, Michiel S. van der Heijden, Beiying Ding, Robert Dreicer
Publikováno v:
Journal of Clinical Oncology. 37:4527-4527
4527 Background: Atezo (anti–PD-L1) has been shown to elicit CRs in a number of mUC patients (pts) in clinical trials. We sought to describe the kinetics, durability and outcomes associated with these CRs in Ph I (PCD) and II (IMvigor210) atezo stu
Autor:
Constanze Kaiser, Frede Donskov, Michael B. Atkins, Toni K. Choueiri, U. De Giorgi, Lawrence Fong, Tarik Khaznadar, David F. McDermott, Brian I. Rini, Darren Tayama, F. Di Nucci, Robert J. Motzer, Yulei Wang, Bernard Escudier, Sumanta K. Pal, Thomas Powles, Cristina Suarez
Publikováno v:
Annals of Oncology. 29:viii308
Publikováno v:
Nature Structural & Molecular Biology. 19:603-608
Polyadenylated mRNAs are typically more strongly repressed by microRNAs (miRNAs) than their nonadenylated counterparts. Using a Drosophila melanogaster cell-free translation system, we found that this effect is mediated by the poly(A)-binding protein
Publikováno v:
Molecular and Cellular Biology. 30:5160-5167
The m(7)G cap binding protein eukaryotic initiation factor 4E (eIF4E) is a rate-limiting determinant of protein synthesis. Elevated eIF4E levels, commonly associated with neoplasia, promote oncogenesis, and phosphorylation of eIF4E at Ser209 is criti